Patents by Inventor Signe Erickson
Signe Erickson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240139027Abstract: An apparatus to treat a patient comprises a container to receive fluid of a device implanted in the eye. The fluid of the device can be analyzed to determine a component of the vitreous humor of the eye.Type: ApplicationFiled: October 6, 2023Publication date: May 2, 2024Inventors: Signe Erickson, Darren Doud, Eugene de Juan, JR., Yair Alster, Cary J. Reich, Kathleen Cogan Farinas
-
Patent number: 11906719Abstract: Systems and methods can be employed for trans-tympanic membrane access to the middle ear for delivery of a formulation or implant device to a target location under direct visualization. The systems and methods can also be used to improve accessibility and visualization for various otological surgical procedures, such as, but not limited to, cholesteatoma removal, tympanic membrane repair and ossicular chain repair.Type: GrantFiled: January 22, 2021Date of Patent: February 20, 2024Assignee: Spiral Therapeutics Inc.Inventors: Eugene de Juan, Hugo Peris, Signe Erickson, Vrad Levering
-
Publication number: 20240019674Abstract: Devices, systems, and methods can be employed to facilitate indirect viewing into cavities such as, but not limited to, the middle ear space. Some embodiments have uses such as, but not limited to, facilitating visualization and procedures in the outer, middle, and/or inner ear in order to diagnose and/or treat disorders including, but not limited to, hearing loss and other ear disorders. In particular implementations, a surgical microscope is used in conjunction with an inverter lens and a distal lens. In some cases, the distal lens transverses a membrane or septum such as, but not limited to, the tympanic membrane. The distal lens can be an assembly combining two or more lenses, in some embodiments. For example, in some cases wide angle lenses, zoom lenses, lenses of other various shapes and/or prisms can be used in the distal lens.Type: ApplicationFiled: September 18, 2023Publication date: January 18, 2024Inventors: Eugene de Juan, Signe Erickson, Vrad Levering
-
Patent number: 11813196Abstract: An apparatus to treat a patient comprises a container to receive fluid of a device implanted in the eye. The fluid of the device can be analyzed to determine a component of the vitreous humor of the eye.Type: GrantFiled: August 14, 2019Date of Patent: November 14, 2023Assignee: ForSight Vision4, Inc.Inventors: Signe Erickson, Darren Doud, Eugene de Juan, Jr., Yair Alster, Cary J. Reich, Kathleen Cogan Farinas
-
Patent number: 11796781Abstract: Devices, systems, and methods can be employed to facilitate indirect viewing into cavities such as, but not limited to, the middle ear space. Some embodiments have uses such as, but not limited to, facilitating visualization and procedures in the outer, middle, and/or inner ear in order to diagnose and/or treat disorders including, but not limited to, hearing loss and other ear disorders. In particular implementations, a surgical microscope is used in conjunction with an inverter lens and a distal lens. In some cases, the distal lens transverses a membrane or septum such as, but not limited to, the tympanic membrane. The distal lens can be an assembly combining two or more lenses, in some embodiments. For example, in some cases wide angle lenses, zoom lenses, lenses of other various shapes and/or prisms can be used in the distal lens.Type: GrantFiled: January 22, 2021Date of Patent: October 24, 2023Assignee: Spiral Therapeutics Inc.Inventors: Eugene de Juan, Signe Erickson, Vrad Levering
-
Patent number: 11786396Abstract: Methods and apparatus provide a therapeutic fluid to devices implanted in the body, for example to containers of devices implanted in the eye of a patient. The methods and apparatus may comprise an injector to increase an amount of therapeutic agent injected into the device implanted in the eye, or a structure to receive the therapeutic fluid within the device implanted in the eye, or combinations thereof. The device implanted in the eye may comprise a reservoir chamber having a fluid with a density different than the therapeutic fluid, and the apparatus can be adapted to at least partially separate the implanted device fluid from therapeutic fluid within the reservoir chamber to increase and amount of therapeutic fluid placed in the reservoir chamber.Type: GrantFiled: April 17, 2019Date of Patent: October 17, 2023Assignee: ForSight Vision4, Inc.Inventors: Eugene de Juan, Jr., Yair Alster, Kathleen Cogan Farinas, K. Angela Macfarlane, Cary J. Reich, Randolph E. Campbell, Darren Doud, Signe Erickson, Mike Barrett, David Batten, Christina Skieller, Greg Stine
-
Publication number: 20230258915Abstract: Systems and methods can be employed for trans-tympanic membrane access to the middle ear for delivery of a therapeutic agent, for example, to the round window niche adjacent to the cochlea under direct visualization. The systems and methods can also be used to improve accessibility and visualization for various otological surgical procedures, such as, but not limited to, cholesteatoma removal, tympanic membrane repair and ossicular chain repair.Type: ApplicationFiled: April 24, 2023Publication date: August 17, 2023Inventors: Eugene de Juan, Signe Erickson, Charles Limb, Hugo Peris, Andrew Ayoob, Vrad Levering
-
Publication number: 20230225903Abstract: Described are implantable devices having reservoirs for the sustained release of therapeutic agents. The devices are configured to be at least partially implanted in an eye and include a retention structure and a penetrable element coupled to and extending within at least a portion of the proximal end region of the device. The device includes a porous drug release element is positioned in fluid communication with an outlet of the device and a reservoir having a volume configured to contain one or more therapeutic agents in fluid communication with the outlet through the porous drug release element. The device is at least partially inserted along an axis of insertion.Type: ApplicationFiled: February 14, 2023Publication date: July 20, 2023Inventors: Randolph E. Campbell, Kevin W. Sacheman, Bradley G. Bachelder, Signe Erickson, Jeremy Boyette
-
Patent number: 11679027Abstract: Methods and apparatus provide treatment with a first therapeutic agent and a second therapeutic agent for an extended time. The first therapeutic agent may comprise a VEGF inhibitor and the second therapeutic agent may comprise an antiinflammatory, such as a non-steroidal anti-inflammatory, for example a cyclooxygenase inhibitor. One or more of the first therapeutic agent or the second therapeutic agent can be injected into the eye, for example injected into a therapeutic device implanted into the eye to release the injected therapeutic agent for an extended time.Type: GrantFiled: March 4, 2020Date of Patent: June 20, 2023Assignee: ForSight Vision4, Inc.Inventors: Eugene de Juan, Jr., Yair Alster, Kathleen Cogan Farinas, Cary J. Reich, Randolph E. Campbell, K. Angela MacFarlane, Signe Erickson
-
Publication number: 20230183475Abstract: Provided herein are polymer compositions and extended release otic agents. In one aspect, provided herein is a polymer composition including about 5% to about 15% by weight of the polymer composition of a functional polymer, wherein the functional polymer includes a first functional group, about 0.05% to about 0.6% by weight of the polymer composition of a crosslinker, wherein the crosslinker includes a second functional group, and water, wherein a crosslinking reaction can occur between the first functional group and the second functional group to form a gel, and wherein the polymer composition has a gelation time of about 45 seconds to about 60 minutes at a temperature of about 20° C.Type: ApplicationFiled: May 12, 2021Publication date: June 15, 2023Inventors: Eugene de Juan, JR., Signe Erickson, Andrew Ayoob, Kathleen Farinas
-
Patent number: 11662561Abstract: Systems and methods can be employed for trans-tympanic membrane access to the middle ear for delivery of a therapeutic agent, for example, to the round window niche adjacent to the cochlea under direct visualization. The systems and methods can also be used to improve accessibility and visualization for various otological surgical procedures, such as, but not limited to, cholesteatoma removal, tympanic membrane repair and ossicular chain repair.Type: GrantFiled: January 22, 2021Date of Patent: May 30, 2023Assignee: Spiral Therapeutics Inc.Inventors: Eugene de Juan, Signe Erickson, Charles Limb, Hugo Peris, Andrew Ayoob, Vrad Levering
-
Publication number: 20230145887Abstract: Described are implantable therapeutic devices, systems and methods to treat a patient. The device includes a hollow refillable housing for implantation within the posterior segment of an eye through a penetration in the sclera including a proximal retention structure protruding outward from a proximal end region of the housing, an access portion opening, and a penetrable barrier positioned at least in part within the access portion opening, the penetrable barrier configured to be repeatedly penetrated. A rigid porous structure is positioned within a region of the housing away from the access portion opening into a reservoir chamber extends along an axis between the penetrable barrier and the porous structure includes a volume sized to deliver therapeutic amounts of a therapeutic agent to the eye for an extended period of time. A cover is coupled to at least an upper surface of the proximal retention structure.Type: ApplicationFiled: October 26, 2022Publication date: May 11, 2023Inventors: Signe Erickson, Randolph E. Campbell, Darren Doud
-
Patent number: 11617680Abstract: An implantable device having a reservoir for the sustained release of therapeutic agents. The device is configured to be at least partially implanted in an eye and include a retention structure and a penetrable element coupled to and extending within at least a portion of the proximal end region of the device. The device includes a porous drug release element is positioned in fluid communication with an outlet of the device and a reservoir having a volume configured to contain one or more therapeutic agents in fluid communication with the outlet through the porous drug release element. The device is at least partially inserted along an axis of insertion.Type: GrantFiled: April 5, 2017Date of Patent: April 4, 2023Assignee: ForSight Vision4, Inc.Inventors: Randolph E. Campbell, Kevin W. Sacherman, Bradley G. Bachelder, Signe Erickson, Jeremy Boyette
-
Publication number: 20230072346Abstract: A therapeutic device for extended release drug delivery including a refillable reservoir configured to receive a therapeutic agent and having an outlet for delivery of the therapeutic agent to a patient from the reservoir over an extended period. A porous structure is coupled near the outlet of the reservoir, the porous structure formed of sintered material. A barrier layer is coupled to the reservoir on or adjacent a surface of the porous structure such that the therapeutic agent passes through both the porous structure and the barrier layer upon delivery from the reservoir through the outlet. The porous structure is tuned to deliver the therapeutic agent at a diffusion rate and the barrier layer is adapted to block passage of particles having an average particle size within an average particle size range that is outside an average particle size range blocked by the porous structure. Related methods and systems are provided.Type: ApplicationFiled: July 29, 2022Publication date: March 9, 2023Inventors: Randolph E. Campbell, Kevin W. Sacherman, Kathleen Cogan Farinas, Signe Erickson, Jeremy Boyette
-
Publication number: 20230067496Abstract: Active agents that bind to VEGF or a VEGF receptor and reduce the severity of a condition associated with BLB disruption and/or angiogenesis, for example anti-VEGF antibodies or tyrosine kinase inhibitor small molecules, can be locally, regionally or systemically administered to an individual with an otic disease or condition, such as Méniére's Disease, Autoimmune Inner Ear Disease, sensorineural hearing loss and noise-induced hearing loss, to alleviate symptoms of the disease or condition, for example, due to edema and endolymphatic dysfunction. An effective amount of these compounds can be delivered by intratympanic or intracochlear administration. Other methods of administration include, but are not limited to, topical, parenteral, subcutaneous, intraperitoneal and intranasal. Formulations may be, for example, for immediate release, sustained release, or controlled release.Type: ApplicationFiled: February 12, 2021Publication date: March 2, 2023Inventors: Eugene de Juan, Jr., Andrew Ayoob, Signe Erickson, Kathleen Farinas
-
Patent number: 11510810Abstract: Described are implantable therapeutic devices, systems and methods to treat a patient. The device includes a hollow refillable housing for implantation within the posterior segment of an eye through a penetration in the sclera including a proximal retention structure protruding outward from a proximal end region of the housing, an access portion opening, and a penetrable barrier positioned at least in part within the access portion opening, the penetrable barrier configured to be repeatedly penetrated. A rigid porous structure is positioned within a region of the housing away from the access portion opening into a reservoir chamber extends along an axis between the penetrable barrier and the porous structure includes a volume sized to deliver therapeutic amounts of a therapeutic agent to the eye for an extended period of time. A cover is coupled to at least an upper surface of the proximal retention structure.Type: GrantFiled: July 17, 2019Date of Patent: November 29, 2022Assignee: ForSight Vision4, Inc.Inventors: Signe Erickson, Randolph E. Campbell, Darren Doud
-
Publication number: 20220363742Abstract: Active agents that bind to VEGF or a VEGF receptor and reduce the severity of a condition associated with BLB disruption and/or angiogenesis, for example anti-VEGF antibodies or tyrosine kinase inhibitor small molecules, can be locally, regionally or systemically administered to an individual with Meniere's Disease to alleviate symptoms of the disease, for example, due to edema and endolymphatic dysfunction. An effective amount of these compounds can be delivered by intratympanic or intracochlear administration. Other methods of administration include, but are not limited to, topical, parenteral, subcutaneous, intraperitoneal and intranasal. Formulations may be, for example, for immediate release, sustained release, or controlled release.Type: ApplicationFiled: November 6, 2020Publication date: November 17, 2022Inventors: Eugene de Juan, Andrew Ayoob, Signe Erickson, Kathleen Farinas
-
Patent number: 11467386Abstract: Systems and methods can be employed for trans-tympanic membrane access to the middle ear for delivery of a therapeutic agent, for example, to the round window niche adjacent to the cochlea under direct visualization. The systems and methods can also be used to improve accessibility and visualization for various otological surgical procedures, such as, but not limited to, cholesteatoma removal, tympanic membrane repair and ossicular chain repair.Type: GrantFiled: March 30, 2022Date of Patent: October 11, 2022Assignee: Spiral Therapeutics Inc.Inventors: Eugene de Juan, Signe Erickson, Charles Limb, Hugo Peris, Andrew Ayoob, Vrad Levering
-
Patent number: 11432959Abstract: A therapeutic device for extended release drug delivery including a refillable reservoir configured to receive a therapeutic agent and having an outlet for delivery of the therapeutic agent to a patient from the reservoir over an extended period. A porous structure is coupled near the outlet of the reservoir, the porous structure formed of sintered material. A barrier layer is coupled to the reservoir on or adjacent a surface of the porous structure such that the therapeutic agent passes through both the porous structure and the barrier layer upon delivery from the reservoir through the outlet. The porous structure is tuned to deliver the therapeutic agent at a diffusion rate and the barrier layer is adapted to block passage of particles having an average particle size within an average particle size range that is outside an average particle size range blocked by the porous structure. Related methods and systems are provided.Type: GrantFiled: November 18, 2016Date of Patent: September 6, 2022Assignee: ForSight Vision4, Inc.Inventors: Randolph E. Campbell, Kevin W. Sacherman, Kathleen Cogan Farinas, Signe Erickson, Jeremy Boyette
-
Publication number: 20220249815Abstract: An implantable device for delivering a therapeutic agent to treat an ear of a patient includes a body having a distal end region and a proximal end region. The body defines, at least in part, a reservoir configured to contain the therapeutic agent. The device includes a shaft attached to the distal end region of the body and a lumen extending through the shaft having at least one inlet at a proximal end region in fluid communication with the reservoir and at least one outlet at a distal end region. Upon implantation of the body in a region of the ear, a length of the shaft is sufficient to extend from the body to at least the round window membrane of the ear. The device is configured to deliver the therapeutic agent to the ear from the reservoir via passive diffusion. Related devices and methods are described.Type: ApplicationFiled: February 9, 2022Publication date: August 11, 2022Inventors: Kevin W. Sacherman, Signe Erickson, Hugo Peris, Eugene de Juan, JR.